Portugal now part of MRA with FDA
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
After a positive assessment, the US Food and Drug Administration (FDA) has approved Portugal to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
The total number of countries accepted by the FDA is now 15: Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Other EU member states will be added as their evaluation is completed by the US. According to a previous EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Source: EMA Press Release entitled "Portugal to also benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections
19.03.2025ICMRA publishes Hybrid Inspection Pilot Summary Report
19.03.2025From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products
19.03.2025Warning Letter - Deficiencies in the Control of Raw and Starting Materials
19.03.2025Inadequate Microbiological Testing of Nonsterile Products - FDA Warning Letter